https://www.selleckchem.com/pr....oducts/pyrotinib.htm
002). The bioactive nIL-24, developed through this study, holds promise for use in further functional characterizations/applications. KEY POINTS • Yeast SUMO fusion partner at N-terminus for improved solubility of an otherwise insoluble IL-24 in E. coli. • Enhanced cell densities with concomitant several-fold increase in protein yield by lactose-inducible media. • Improved inhibition of cervical and colorectal carcinomas by native-like nIL-24 compared with Met-containing IL. • Heterologous nIL-24 may enable better understanding of the
Like
Comment
Share
